Elisabeth Naschberger

Prof. Dr. Elisabeth Naschberger

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2014 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CSChristine Schauer
Christine Schauer
CJChristina Janko
Christina Janko
Luis MunozLuis Munoz
Luis Munoz
YZYi Zhao
Yi Zhao
DKDeborah Kienhöfer
Deborah Kienhöfer
Martin HerrmannMartin Herrmann
Martin Herrmann

30 September 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
VLVictoria Langer
Victoria Langer
EVEugenia Vivi
Eugenia Vivi
DRDaniela Regensburger
Daniela Regensburger
TWThomas H. Winkler
Thomas H. Winkler
MWMaximilian J. Waldner
Maximilian J. Waldner
Michael StürzlMichael Stürzl
Michael Stürzl
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder with rising incidence. Diseased tissues are heavily vascularized. Surprisingly, the pathogenic impact of the vasculature in IBD and the underlying regulatory mechanisms remain largely unknown. IFN-γ is a major cytokine in IBD pathogenesis, but in the context of the disease, it is almost exclusively its immune-modulatory and epithelial cell-directed functions that have been considered. Recent studies by our group demonstrated that IFN-γ also exerts potent effects on blood vessels. Based on these considerations, we analyzed the vessel-directed pathogenic functions of IFN-γ and found that it drives IBD pathogenesis through vascular barrier disruption. Specifically, we show that inhibition of the IFN-γ response in vessels by endothelial-specific knockout of IFN-γ receptor 2 ameliorates experimentally induced colitis in mice. IFN-γ acts pathogenic by causing a breakdown of the vascular barrier through disruption of the adherens junction protein VE-cadherin. Notably, intestinal vascular barrier dysfunction was also confirmed in human IBD patients, supporting the clinical relevance of our findings. Treatment with imatinib restored VE-cadherin/adherens junctions, inhibited vascular permeability, and significantly reduced colonic inflammation in experimental colitis. Our findings inaugurate the pathogenic impact of IFN-γ-mediated intestinal vessel activation in IBD and open new avenues for vascular-directed treatment of this disease.

27 May 2012 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AHAlexander S Hahn
Alexander S Hahn
JKJohanna K Kaufmann
Johanna K Kaufmann
EWEffi Wies
Effi Wies
ENElisabeth Naschberger
Elisabeth Naschberger
JPJulia Panteleev-Ivlev
Julia Panteleev-Ivlev
FNFrank Neipel
Frank Neipel

30 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
TWThomas Wohlfahrt
Thomas Wohlfahrt
SRSimon Rauber
Simon Rauber
SUSteffen Uebe
Steffen Uebe
MLMarkus Luber
Markus Luber
ASAlina Soare
Alina Soare
ARAndreas Ramming
Andreas Ramming

1 August 2003 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
EGEric Guenzi
Eric Guenzi
KTKristin Töpolt
Kristin Töpolt
CLClara Lubeseder‐Martellato
Clara Lubeseder‐Martellato
AJAnita Jörg
Anita Jörg
ENElisabeth Naschberger
Elisabeth Naschberger
Michael StürzlMichael Stürzl
Michael Stürzl

7 December 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NBNathalie Britzen-Laurent
Nathalie Britzen-Laurent
MBMichael Bauer
Michael Bauer
VBValeria Berton
Valeria Berton
NFNicole Fischer
Nicole Fischer
ASAdrian Syguda
Adrian Syguda
Michael StürzlMichael Stürzl
Michael Stürzl
Guanylate-binding proteins (GBPs) belong to the dynamin family of large GTPases and represent the major IFN-γ-induced proteins. Here we systematically investigated the mechanisms regulating the subcellular localization of GBPs. Three GBPs (GBP-1, GBP-2 and GBP-5) carry a C-terminal CaaX-prenylation signal, which is typical for small GTPases of the Ras family, and increases the membrane affinity of proteins. In this study, we demonstrated that GBP-1, GBP-2 and GBP-5 are prenylated in vivo and that prenylation is required for the membrane association of GBP-1, GBP-2 and GBP-5. Using co-immunoprecipitation, yeast-two-hybrid analysis and fluorescence complementation assays, we showed for the first time that GBPs are able to homodimerize in vivo and that the membrane association of GBPs is regulated by dimerization similarly to dynamin. Interestingly, GBPs could also heterodimerize. This resulted in hierarchical positioning effects on the intracellular localization of the proteins. Specifically, GBP-1 recruited GBP-5 and GBP-2 into its own cellular compartment and GBP-5 repositioned GBP-2. In addition, GBP-1, GBP-2 and GBP-5 were able to redirect non-prenylated GBPs to their compartment in a prenylation-dependent manner. Overall, these findings prove in vivo the ability of GBPs to dimerize, indicate that heterodimerization regulates sub-cellular localization of GBPs and underscore putative membrane-associated functions of this family of proteins.